| Catalog No. | Size | Price (USD) |
| 10400-MM08-P-25 | 25 Tests | $44.43 |
| 10400-MM08-P-100 | 100 Tests | $103.68 |
General Information
| Product name | Anti-CD4 Antibody (PE), Mouse Monoclonal |
| Validated applications | FCM (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human CD4 |
| Immunogen | Recombinant Human CD4 protein (Catalog#10400-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD4 (rh CD4; Catalog#10400-H08H; NP_000607.1; Met1-Trp390) and conjugated with PE under optimum conditions, the unreacted PE was removed. |
| Source | Monoclonal Mouse IgG1 Clone #08 |
| Purification | Protein A |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Concentration | 1 μl/Test, 0.1 mg/ml |
| Conjugate | PE |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! |
Synonyms: Anti-CD4mut Antibody; Anti-IMD79 Antibody; Anti-Leu-3 Antibody; Anti-OKT4D Antibody; Anti-T4 Antibody
Image / Experimental Information
| Image 1 Description | Flow cytometric analysis of Human CD4 expression on human peripheral blood lymphocytes. Cells were stained with PE-conjugated anti-Human CD4 and FITC conjugated anti-Human CD3 (BD Pharmingen™ Cat. No. 555332). The dot plots were derived from events with the forward and side light-scatter characteristics of viable lymphocytes. |
| Image 1 Alt Text | Human CD4 Flow Cytometry (FC) 22113 |
| Image 1 URL | Source image |
Background Information
| Full Name | CD4 molecule |
| Description | T-cell surface glycoprotein CD4, is a single-pass type I membrane protein. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. The CD4 surface determinant, previously associated as a phenotypic marker for helper/inducer subsets of T lymphocytes, has now been critically identified as the binding/entry protein for human immunodeficiency viruses (HIV). The human CD4 molecule is readily detectable on monocytes, T lymphocytes, and brain tissues. All human tissue sources of CD4 bind radiolabeled gp120 to the same relative degree; however, the murine homologous protein, L3T4, does not bind the HIV envelope protein. CD4 is a co-receptor that assists the T cell receptor (TCR) to activate its T cell following an interaction with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR. CD4 interacts directly with MHC class II molecules on the surface of the antigen-presenting cell via its extracellular domain. The CD4 molecule is currently the object of intense interest and investigation both because of its role in normal T-cell function, and because of its role in HIV infection. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Viral protein U (VpU) of HIV-1 plays an important role in downregulation of the main HIV-1 receptor CD4 from the surface of infected cells. Physical binding of VpU to newly synthesized CD4 in the endoplasmic reticulum is an early step in a pathway leading to proteasomal degradation of CD4. Amino acids in both helices found in the cytoplasmic region of VpU in membrane-mimicking detergent micelles experience chemical shift perturbations upon binding to CD4, whereas amino acids between the two helices and at the C-terminus of VpU show no or only small changes, respectively. Paramagnetic spin labels were attached at three sequence positions of a CD4 peptide comprising the transmembrane and cytosolic domains of the receptor. VpU binds to a membrane-proximal region in the cytoplasmic domain of CD4. |
| Related Pathways |
|
| References |
|
title: Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
authors: Jie Chen; Zhidi Pan; ...; Jianwei Zhu
journal: Heliyon
date: 2023-07-04
doi: 10.1016/j.heliyon.2023.e17960
pmcid: 10344817
cited_by_count: 3
techniques: Activation Assay; Enzyme-linked Immunosorbent Assay; Expressing; Flow Cytometry; Fluorescence; Incubation
bioz_score: 91
title: A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
authors: Jie Chen; Zhidi Pan; ...; Paola Maroni
journal: Biomedicines
date: 2021-08-20
pmid: 34440263
doi: 10.3390/biomedicines9081059
pmcid: 8393954
cited_by_count: 18
techniques: Activation Assay; Activity Assay; Cell Culture; Expressing; Flow Cytometry; Fluorescence; In Vivo; Incubation; Staining; Two Tailed Test
bioz_score: 91
title: Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
authors: Triparna Sen; Carminia M. Della Corte; ...; Lauren A Byers
journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
date: 2020-02-18
pmid: 31470128
doi: 10.1016/j.jtho.2019.08.009
pmcid: 7141083
cited_by_count: 105
techniques: Immunohistochemical staining; Immunohistochemistry; Microscopy; Staining
bioz_score: 90
title: Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling
authors: Elise V. Mike; Hadijat M. Makinde; ...; Chaim Putterman
journal: Frontiers in Immunology
date: 2018-09-26
pmid: 30319641
doi: 10.3389/fimmu.2018.02189
pmcid: 6168636
cited_by_count: 43
techniques: Control; Flow Cytometry; Immunofluorescence; Immunostaining; Staining
bioz_score: 90
